PMC:5400020 / 5296-6424 JSONTXT

{"project":"0_colil","denotations":[{"id":"28175264-23026738-6815","span":{"begin":410,"end":411},"obj":"23026738"}],"text":"Endpoints and definitions\nThe primary endpoint of SAVI-1 was the rate of major cardiac and cerebrovascular events (MACCE) at 30 days and 1 year, defined as composite of death, myocardial infarction, reintervention, and stroke. The primary endpoint of SAVI-2 was the incidence of all-cause mortality at 30 days. Secondary end-points according to the Valvular Academic Research Consortium-2 (VARC-2) guidelines [7] were: mortality, stroke, myocardial infarction, bleeding complications, acute kidney injury, vascular complications, conduction disturbances and arrhythmias, and other TAVI-related complications (i.e. valve-in-valve, conversion to open heart, coronary obstruction, unplanned use of cardiopulmonary bypass, ventricular septal perforation, mitral valve apparatus damage/dysfunction, cardiac tamponade, endocarditis, valve thrombosis, valve migration/embolization) at 30 days and 1 year. Functional improvement from baseline was assessed via the New York Heart Association (NYHA) functional classification at the 30-day and 1-year follow-ups. We intend to compare safety and performance outcomes between SAVI-1 and -2."}

{"project":"2_test","denotations":[{"id":"28175264-23026738-28904981","span":{"begin":410,"end":411},"obj":"23026738"}],"text":"Endpoints and definitions\nThe primary endpoint of SAVI-1 was the rate of major cardiac and cerebrovascular events (MACCE) at 30 days and 1 year, defined as composite of death, myocardial infarction, reintervention, and stroke. The primary endpoint of SAVI-2 was the incidence of all-cause mortality at 30 days. Secondary end-points according to the Valvular Academic Research Consortium-2 (VARC-2) guidelines [7] were: mortality, stroke, myocardial infarction, bleeding complications, acute kidney injury, vascular complications, conduction disturbances and arrhythmias, and other TAVI-related complications (i.e. valve-in-valve, conversion to open heart, coronary obstruction, unplanned use of cardiopulmonary bypass, ventricular septal perforation, mitral valve apparatus damage/dysfunction, cardiac tamponade, endocarditis, valve thrombosis, valve migration/embolization) at 30 days and 1 year. Functional improvement from baseline was assessed via the New York Heart Association (NYHA) functional classification at the 30-day and 1-year follow-ups. We intend to compare safety and performance outcomes between SAVI-1 and -2."}

{"project":"MyTest","denotations":[{"id":"28175264-23026738-28904981","span":{"begin":410,"end":411},"obj":"23026738"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Endpoints and definitions\nThe primary endpoint of SAVI-1 was the rate of major cardiac and cerebrovascular events (MACCE) at 30 days and 1 year, defined as composite of death, myocardial infarction, reintervention, and stroke. The primary endpoint of SAVI-2 was the incidence of all-cause mortality at 30 days. Secondary end-points according to the Valvular Academic Research Consortium-2 (VARC-2) guidelines [7] were: mortality, stroke, myocardial infarction, bleeding complications, acute kidney injury, vascular complications, conduction disturbances and arrhythmias, and other TAVI-related complications (i.e. valve-in-valve, conversion to open heart, coronary obstruction, unplanned use of cardiopulmonary bypass, ventricular septal perforation, mitral valve apparatus damage/dysfunction, cardiac tamponade, endocarditis, valve thrombosis, valve migration/embolization) at 30 days and 1 year. Functional improvement from baseline was assessed via the New York Heart Association (NYHA) functional classification at the 30-day and 1-year follow-ups. We intend to compare safety and performance outcomes between SAVI-1 and -2."}

{"project":"testtesttest","denotations":[{"id":"T23","span":{"begin":491,"end":497},"obj":"Body_part"},{"id":"T24","span":{"begin":614,"end":619},"obj":"Body_part"},{"id":"T25","span":{"begin":623,"end":628},"obj":"Body_part"},{"id":"T26","span":{"begin":649,"end":654},"obj":"Body_part"},{"id":"T30","span":{"begin":751,"end":763},"obj":"Body_part"},{"id":"T31","span":{"begin":827,"end":832},"obj":"Body_part"},{"id":"T32","span":{"begin":845,"end":850},"obj":"Body_part"},{"id":"T33","span":{"begin":965,"end":970},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0003978"},{"id":"A25","pred":"uberon_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/UBERON_0003978"},{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A27","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"A28","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"A29","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0015230"},{"id":"A30","pred":"uberon_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/UBERON_0002135"},{"id":"A31","pred":"uberon_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/UBERON_0003978"},{"id":"A32","pred":"uberon_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/UBERON_0003978"},{"id":"A33","pred":"uberon_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A34","pred":"uberon_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"A35","pred":"uberon_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"A36","pred":"uberon_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/UBERON_0015230"}],"text":"Endpoints and definitions\nThe primary endpoint of SAVI-1 was the rate of major cardiac and cerebrovascular events (MACCE) at 30 days and 1 year, defined as composite of death, myocardial infarction, reintervention, and stroke. The primary endpoint of SAVI-2 was the incidence of all-cause mortality at 30 days. Secondary end-points according to the Valvular Academic Research Consortium-2 (VARC-2) guidelines [7] were: mortality, stroke, myocardial infarction, bleeding complications, acute kidney injury, vascular complications, conduction disturbances and arrhythmias, and other TAVI-related complications (i.e. valve-in-valve, conversion to open heart, coronary obstruction, unplanned use of cardiopulmonary bypass, ventricular septal perforation, mitral valve apparatus damage/dysfunction, cardiac tamponade, endocarditis, valve thrombosis, valve migration/embolization) at 30 days and 1 year. Functional improvement from baseline was assessed via the New York Heart Association (NYHA) functional classification at the 30-day and 1-year follow-ups. We intend to compare safety and performance outcomes between SAVI-1 and -2."}